+0.00%
Today
Loading 1D prices…
Company profile
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Diego, CA, United States
Employees
28
Fiscal year end
1231
CIK
1782303
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TLPHTalphera Inc. Common Stock | $64.4M | $28K | -51035.71% | -$0.34 | 0.00% | Buy |
| NMADNomad Power Solutions Inc. Common Stock | $64.7M | $0.00 | — | -$1.26 | -4.58% | Unrated |
| GOSSGossamer Bio Inc. Common Stock | $65.6M | $48.5M | -351.49% | -$0.75 | -6.12% | Hold |
| SPROSpero Therapeutics Inc. Common Stock | $65.8M | $12.6M | +68.11% | $0.15 | +0.89% | Buy |
| DWTXDogwood Therapeutics Inc. Common Stock | $65.9M | $0.00 | — | -$7.13 | +3.19% | Buy |